Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in Acute Coronary Syndromes (REPRESS): Study Protocol for a Multicenter Randomized Controlled Trial

Next Previous
Trial Profile

PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in Acute Coronary Syndromes (REPRESS): Study Protocol for a Multicenter Randomized Controlled Trial

Status: Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Dec 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Inclisiran (Primary) ; Alirocumab; Atorvastatin; Evolocumab; Rosuvastatin
  • Indications Acute coronary syndromes
  • Focus Therapeutic Use
  • Acronyms REPRESS

Most Recent Events

  • 28 Nov 2025 Treatments section is updated to add Alirocumab and Evolocumab in combination with the study drug. Planned enrollment is increased and primary end point is changed.
  • 28 Nov 2025 Planned number of patients changed from 180 to 212.
  • 28 Nov 2025 Planned End Date changed from 1 Dec 2026 to 1 Jun 2028.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top